Base metrics
- Operating margin
- 31.1%
- Interest coverage
- 20.8x
- Return on equity (ROE)
- 23.2%
BIOBIJOU
489460 · KOSDAQ₩11,180+2.10%
2026-09-04 closeBIOBIJOU last closed at ₩11,180 (+2.10%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
Super Strong RS 85 · top 15%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 11.57
Distress
Grey
Safe
- Altman Z''
- 11.57
- Beneish M-Score
- —
- Sloan accrual
- 17.54%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
TolerableInterest coverageBase 20.8x adverse case 17.4x
Return on equity (ROE)Base 23.2% adverse case 23.6%
Revenue −15%
TolerableInterest coverageBase 20.8x adverse case 17.7x
Return on equity (ROE)Base 23.2% adverse case 23.9%
Interest rate +2pp
TolerableInterest coverageBase 20.8x adverse case 15.9x
Return on equity (ROE)Base 23.2% adverse case 27.9%
Interest coverage limit
Current margin 29.6ppInterest coverage limit at an operating margin of 1.5%
Interest expense coverage threshold
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 청담글로벌50.85%2025-05-20 · 증감 +50.85%p
- LICHENGJIE6.98%2025-05-20 · 증감 +6.98%p
- 마이센보유한공사6.22%2025-05-20 · 증감 +6.22%p
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
Recent filings
BIOBIJOU's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About BIOBIJOU
- What technical signals does BIOBIJOU (489460) have?
- BIOBIJOU current technical signals: no active technical signal.
- Is BIOBIJOU a cup-and-handle pattern?
- No. BIOBIJOU has no valid cup-and-handle signal right now.
- What are BIOBIJOU's financials and valuation?
- BIOBIJOU's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy